Aptose Biosciences Inc.
NASDAQ:APTO
Overview | Financials
Company Name | Aptose Biosciences Inc. |
Symbol | APTO |
Currency | USD |
Price | 0.25 |
Market Cap | 14,880,300 |
Dividend Yield | 0% |
52-week-range | 0.13 - 2.68 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. William G. Rice Ph.D. |
Website | https://www.aptose.com |
An error occurred while fetching data.
About Aptose Biosciences Inc.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD